Pharmacological inhibition of the ataxia telangiectasia and Rad3-linked protein serine/threonine kinase (ATR; generally known as FRAP-linked protein (FRP1)) has emerged like a promising tactic for cancer procedure that exploits synthetic lethal interactions with proteins involved in DNA harm repair, overcomes resistance to other therapies and enhances antitumour immunity. Many novel, https://kennethm693lrb8.get-blogging.com/profile